| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | 3-hydroxy-10, 13, 14, 15b-tetramethyl-1, 2, 3, 4, 4a, 5, 6, 6a, 6b, 7, 14, 15a, 15b-tetradecahydro-15h-naphth[2', 1':1, 2]-indeno[5, 6-b]indolizine, its esters, and intermediates thereto | US38639564 | 1964-07-30 | US3228951A | 1966-01-11 | JOHNS WILLIAM F; IVAR LAOS |
| 122 | 17alpha-ethynyl-17beta-hydroxy-a-nor-b-homoestranes and their process of preparation | US14922261 | 1961-11-01 | US3192266A | 1965-06-29 | GEORGES MULLER; ANDRE POITTEVIN |
| 123 | Dehydro derivatives of d-homo-c-norestranes and intermediates thereto | US8865161 | 1961-02-13 | US3155729A | 1964-11-03 | JOHNS WILLIAM F |
| 124 | A-nor-b-homo-steroids and process of preparing same | US14922361 | 1961-11-01 | US3040093A | 1962-06-19 | GEORGES MULLER; ANDRE POITTEVIN; ROLAND BARDONESCHI |
| 125 | METHOD OF TREATING SHIP1-MEDIATED DISEASES USING PELOROL DERIVATIVES | US17920169 | 2021-04-20 | US20230174571A1 | 2023-06-08 | Xiao-Yan Wen; Raymond John Andersen; Alice Low-Fung Mui; Yuanyuan Zhao |
| Provided are compounds of Formula I and pharmaceutically acceptable salt, solvate and/or derivative thereof. Further, provided are methods of treating a disease, disorder or condition mediated or treatable by activation of SHIP1 comprising administering a compound of Formula I or a pharmaceutically acceptable salt, solvate or derivative thereof. The compound of Formula I or a pharmaceutically acceptable salt, solvate or derivative thereof may be used in the treatment of SHIP1 mediated disease, disorder or conditions including inflammatory bowel disease (IBD), Crohn' disease, ulcerative colitis, multiple myeloma, liver injury, acute hepatitis and severe sepsis. | ||||||
| 126 | Cyclopamine analogs | US16521447 | 2019-07-24 | US11007181B2 | 2021-05-18 | Brian Austad; Mark L. Behnke; Alfredo C. Castro; Michael J. Grogan; Somarajannair Janardanannair; Andre Lescarbeau; Stephane Peluso; Andre B. Charette; Martin R. Tremblay |
| The invention provides derivatives of cyclopamine having the following formula: | ||||||
| 127 | Complex and structurally diverse compounds | US16136830 | 2018-09-20 | US10800730B2 | 2020-10-13 | Paul J. Hergenrother; Robert W. Huigens, III; Karen C. Morrison; Robert W. Hicklin, II; Timothy A. Flood, Jr. |
| The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product. | ||||||
| 128 | CYCLOPAMINE ANALOGS | US16521447 | 2019-07-24 | US20200121658A1 | 2020-04-23 | Brian Austad; Mark L. Behnke; Alfredo C. Castro; Michael J. Grogan; Somarajannair Janardanannair; Andre Lescarbeau; Stephane Peluso; Andre B. Charette; Martin R. Tremblay |
| The invention provides derivatives of cyclopamine having the following formula: | ||||||
| 129 | Cyclopamine analogs | US15936919 | 2018-03-27 | US10406139B2 | 2019-09-10 | Brian Austad; Mark L. Behnke; Alfredo C. Castro; Michael J. Grogan; Somarajannair Janardanannair; Andre Lescarbeau; Stephane Peluso; Andre B. Charette; Martin R. Tremblay |
| The invention provides derivatives of cyclopamine having the following formula: | ||||||
| 130 | METHODS OF USE OF CYCLOPAMINE ANALOGS | US15585038 | 2017-05-02 | US20170360763A1 | 2017-12-21 | Alfredo C. Castro; Michael J. Grogan; Karen J. McGovern; Martin R. Tremblay |
| The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula: | ||||||
| 131 | Methods of use of cyclopamine analogs | US14841001 | 2015-08-31 | US09669011B2 | 2017-06-06 | Alfredo C. Castro; Michael J. Grogan; Karen J. McGovern; Martin R. Tremblay |
| The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula: | ||||||
| 132 | CYCLOPAMINE ANALOGS | US15289887 | 2016-10-10 | US20170022212A1 | 2017-01-26 | Brian Austad; Mark L. Behnke; Alfredo C. Castro; Michael J. Grogan; Somarajannair Janardanannair; Andre Lescarbeau; Stephane Peluso; Andre B. Charette; Martin R. Tremblay |
| The invention provides derivatives of cyclopamine having the following formula: | ||||||
| 133 | Cyclopamine analogs | US14203297 | 2014-03-10 | US09492435B2 | 2016-11-15 | Brian Austad; Mark L. Behnke; Alfredo C. Castro; Michael J. Grogan; Somarajannair Janardanannair; Andre Lescarbeau; Stephane Peluso; Andre B. Charette; Martin R. Tremblay |
| The invention provides derivatives of cyclopamine having the following formula: | ||||||
| 134 | Methods for obtaining cyclopamine | US12737297 | 2009-07-03 | US09000168B2 | 2015-04-07 | Steven Splinter; Satyasagar Kadali |
| The present invention relates to a process for extracting, purifying and isolating cyclopamine from cyclopamine-containing biomass comprising the steps of contacting cyclopamine-containing organic matter with an extractant (e.g., aqueous extractant) capable of extracting cyclopamine, separating the extracted organic matter from the cyclopamine/extract solution, concentrating the cyclopamine/extract solution leaving a concentrated aqueous solution, contacting the concentrated aqueous solution with an organic extractant capable of selectively extracting cyclopamine from the aqueous phase, concentrating the cyclopamine-containing organic phase, providing an enriched extract containing cyclopamine, separating cyclopamine from the enriched extract using column chromatography, providing at least one fraction containing cyclopamine, and crystallizing select chromatography fractions to provide purified cyclopamine. | ||||||
| 135 | Cyclopamine analogs | US12199689 | 2008-08-27 | US08785635B2 | 2014-07-22 | Brian Austad; Mark L. Behnke; Alfredo C. Castro; Michael J. Grogan; Somarajannair Janardanannair; Andre Lescarbeau; Stephane Peluso; Martin Tremblay |
| The invention provides novel derivatives of cyclopamine having the following formula: | ||||||
| 136 | Process for obtaining a germine adduct from germine values | US1177670 | 1970-02-16 | US3846434A | 1974-11-05 | KUPCHAN S |
| Process for the separation of germine from germine values by treating the germine values with a basic hydrolysis system, removing substantially all of any alkanol which is present in said basic hydrolysis system, forming a solid adduct with the thus liberated germine by contacting the same with a liquid water-immiscible halogenated hydrocarbon. The resulting adduct is useful in preparing germine diacetate.
|
||||||
| 137 | New a-nor-b-homo-steroids | US3758588D | 1969-07-08 | US3758588A | 1973-09-11 | JEGER O; SCHAFFNER K |
| R being -H, an acyl group or a hydrocarbon radical. These compounds have progestative, anti-inflammatory and/or glucocorticoid action.
R9 for -H, -OR R6 for . . H, . . lower alkyl or . . OR R7 for . . H, . . lower alkyl or . . OR WHEREIN X stands for hydrogen or methyl, R1 for H2 or O R being -H, an acyl group or a hydrocarbon radical. A-Nor-B-homo-steroids corresponding to the general formula |
||||||
| 138 | 5 10-seco-19-norandrostenes | US3658916D | 1968-03-18 | US3658916A | 1972-04-25 | MCCRAE WILLIAM; FRIED JOHN H; EDWARDS JOHN A |
| NEW 5,10-SECO-19-NORANDROSTENES PREPARED FROM ESTRA1,3,5(10),6.8-PENTAENES HAVING ESTROGENIC ACTIVITY.
|
||||||
| 139 | Estrogenic b-nor steroids | US3586710D | 1968-11-12 | US3586710A | 1971-06-22 | LOS MARINUS |
| THIS INVENTION RELATES TO B-NOR STEROIDS, A METHOD FOR THE PREPARATION OF SAID COMPOUNDS FROM SIMPLER MOIETIES AND TO THE USE OF SAID COMPOUNDS AS ESTROGENIC AGENTS IN THE TREATMENT OF WARM-BLOODED ANIMALS.
|
||||||
| 140 | 7alpha-difluoromethyl-a-nor-b-homo steroids and their preparation | US3565918D | 1966-09-26 | US3565918A | 1971-02-23 | FRIED JOHN H |
| THE PRESENT DISCLOSURE RELATES TO 3,5-DIOXO-7A-DIFFLUOROMETHYL-A-NOR-B-HOMO ANDROSTANES AND 19-NORANDROSTANES AND DERIVATIVES THEREOF WHERIN THE C-17B POSITION IS ELABORATED WITH A HYDROXYL, TETRAHYDROFURAN - 2 - YLOXY, TETRAHYDROPRAN - 2 - YLOXY OR HYDROCARBON CARBOXYLIC ACYLOXY GROUP OF LESS THAN 12 CARBON ATOMS, AND THE C17A POSITION WITH A HYDROGEN, (LOWER)ALKYL, (LOWER)ALKENYL, (LOWER)ALKYNYL OR HALO(LOWER)ALKYNYL GROUP. THESE COMPOUNDS ARE USEFUL AS ANABOLIC AND ANDROGENIC AGENTS. THOSE COMPOUNDS WHICH BEAR A 17A-ETHYNYL OR -HALOETHYNYL GROUPING ARE ADITIONALLY USEFUL AS PROGRESTATIONAL AGENTS. ALSO TAUGHT IS A METHOD FOR THE PREPARATION OF THESE COMPOUNDS.
|
||||||
QQ群二维码
意见反馈
意见反馈